Clinical trial
Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment…
NCT00234377 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00234377 |
|---|---|
| Title | Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia |
| Official title | A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Seroquel SR |
| Enrollment | 550 |
| Start date | Nov 1, 2004 |
| Completion | May 1, 2006 |
| First posted | Oct 7, 2005 |
| Last update posted | Jan 4, 2013 |
| Countries | Canada, Finland, Germany, Hungary |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: